<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Lipocine Inc — News on 6ix</title>
<link>https://6ix.com/company/lipocine-inc</link>
<description>Latest news and press releases for Lipocine Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 02 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/lipocine-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835931c78dffbe2df1032a4.webp</url>
<title>Lipocine Inc</title>
<link>https://6ix.com/company/lipocine-inc</link>
</image>
<item>
<title>Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression</title>
<link>https://6ix.com/company/lipocine-inc/news/lipocine-reports-topline-safety-and-efficacy-results-for-lpcn-1154-in-patients-with-postpartum-depression-77</link>
<guid isPermaLink="true">https://6ix.com/company/lipocine-inc/news/lipocine-reports-topline-safety-and-efficacy-results-for-lpcn-1154-in-patients-with-postpartum-depression-77</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score</description>
</item>
<item>
<title>Lipocine Announces Financial Results for the Full Year Ended December 31, 2025</title>
<link>https://6ix.com/company/lipocine-inc/news/lipocine-announces-financial-results-for-the-full-year-ended-december-31-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/lipocine-inc/news/lipocine-announces-financial-results-for-the-full-year-ended-december-31-2025-1</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>SALT LAKE CITY, March 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to</description>
</item>
<item>
<title>Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)</title>
<link>https://6ix.com/company/lipocine-inc/news/lipocine-announces-last-patient-last-visit-in-pivotal-phase-3-trial-of-lpcn-1154-for-postpartum-depression-ppd</link>
<guid isPermaLink="true">https://6ix.com/company/lipocine-inc/news/lipocine-announces-last-patient-last-visit-in-pivotal-phase-3-trial-of-lpcn-1154-for-postpartum-depression-ppd</guid>
<pubDate>Wed, 18 Feb 2026 13:00:00 GMT</pubDate>
<description>Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that the last patient has completed the final study visit (Last Patient Last Visit) in its Phase 3 clinical trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD).</description>
</item>
<item>
<title>Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)</title>
<link>https://6ix.com/company/lipocine-inc/news/lipocine-announces-completion-enrollment-dosing-130000223</link>
<guid isPermaLink="true">https://6ix.com/company/lipocine-inc/news/lipocine-announces-completion-enrollment-dosing-130000223</guid>
<pubDate>Tue, 20 Jan 2026 13:00:00 GMT</pubDate>
<description>Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that enrollment and participant dosing have been completed in its Phase 3 clinical trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD).</description>
</item>
<item>
<title>Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)</title>
<link>https://6ix.com/company/lipocine-inc/news/lipocine-reports-encouraging-progress-post-130000279</link>
<guid isPermaLink="true">https://6ix.com/company/lipocine-inc/news/lipocine-reports-encouraging-progress-post-130000279</guid>
<pubDate>Mon, 12 Jan 2026 13:00:00 GMT</pubDate>
<description>Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced the completion of a scheduled independent Data Safety Monitoring Board review of its ongoing Phase 3 clinical trial evaluating LPCN 1154 (oral brexanolone) for the rapid relief treatment of PPD. This was the second of two DSMB reviews planned during the study. The DSMB recommended that the trial continue as planned w</description>
</item>
<item>
<title>Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone</title>
<link>https://6ix.com/company/lipocine-inc/news/lipocines-ppd-phase-3-study-130000931</link>
<guid isPermaLink="true">https://6ix.com/company/lipocine-inc/news/lipocines-ppd-phase-3-study-130000931</guid>
<pubDate>Tue, 16 Dec 2025 13:00:00 GMT</pubDate>
<description>Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced 80% completion of enrollment in the ongoing Phase 3 clinical trial evaluating LPCN 1154 (oral brexanolone) for the rapid relief treatment of PPD, with 66 of the 80 planned study participants randomized. In addition, the second of two independent Data Safety Monitoring Board reviews is planned for early-January 2026.</description>
</item>
<item>
<title>Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)</title>
<link>https://6ix.com/company/lipocine-inc/news/lipocine-highlights-promising-interim-safety-130000989</link>
<guid isPermaLink="true">https://6ix.com/company/lipocine-inc/news/lipocine-highlights-promising-interim-safety-130000989</guid>
<pubDate>Tue, 18 Nov 2025 13:00:00 GMT</pubDate>
<description>Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced the completion of a scheduled independent Data Safety Monitoring Board review of its ongoing Phase 3 clinical trial evaluating LPCN 1154 (oral brexanolone) for the rapid relief treatment of PPD. This was the first of two DSMB reviews planned during the study and conducted after approximately one-third of planned 80 p</description>
</item>
<item>
<title>Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025</title>
<link>https://6ix.com/company/lipocine-inc/news/lipocine-announces-financial-results-third-130000087</link>
<guid isPermaLink="true">https://6ix.com/company/lipocine-inc/news/lipocine-announces-financial-results-third-130000087</guid>
<pubDate>Thu, 06 Nov 2025 13:00:00 GMT</pubDate>
<description>Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the third quarter ended September 30, 2025 and provided a corporate update.</description>
</item>
<item>
<title>Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®</title>
<link>https://6ix.com/company/lipocine-inc/news/lipocine-presents-lpcn-2401-clinical-130000098</link>
<guid isPermaLink="true">https://6ix.com/company/lipocine-inc/news/lipocine-presents-lpcn-2401-clinical-130000098</guid>
<pubDate>Tue, 04 Nov 2025 13:00:00 GMT</pubDate>
<description>Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced the presentation of a poster Treatment with Oral LPCN 2401, a Physiological Regulator of Myostatin, Rapidly Improves Body Composition in Men with Obesity at the ObesityWeek® annual meeting, taking place in Atlanta, Ga., November 4 to 7. The poster features 20-week data from the previously completed Phase 2 trial and</description>
</item>
<item>
<title>Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)</title>
<link>https://6ix.com/company/lipocine-inc/news/lipocine-provides-progress-lpcn-1154-120000626</link>
<guid isPermaLink="true">https://6ix.com/company/lipocine-inc/news/lipocine-provides-progress-lpcn-1154-120000626</guid>
<pubDate>Tue, 30 Sep 2025 12:00:00 GMT</pubDate>
<description>Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today provided an update on its ongoing pivotal Phase 3 clinical trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD). The study is progressing on track with one-third of planned patients randomized. Topline results are anticipated in the second quarter of 2026.</description>
</item>
<item>
<title>Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/lipocine-inc/news/lipocine-present-h-c-wainwright-203000883</link>
<guid isPermaLink="true">https://6ix.com/company/lipocine-inc/news/lipocine-present-h-c-wainwright-203000883</guid>
<pubDate>Fri, 05 Sep 2025 20:30:00 GMT</pubDate>
<description>Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that Company Management will present and meet with investors at the H.C. Wainwright 27th Annual Global Investment Conference being held in-person and virtually on September 8-10, 2025.</description>
</item>
<item>
<title>Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025</title>
<link>https://6ix.com/company/lipocine-inc/news/lipocine-announces-lpcn-2101-abstracts-120000377</link>
<guid isPermaLink="true">https://6ix.com/company/lipocine-inc/news/lipocine-announces-lpcn-2101-abstracts-120000377</guid>
<pubDate>Tue, 26 Aug 2025 12:00:00 GMT</pubDate>
<description>Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that two abstracts related to LPCN 2101 have been accepted for poster presentation at the 2025 American Epilepsy Society (AES) annual meeting to be held December 5-9 in Atlanta, Georgia. LPCN 2101 is in development for the potential treatment of epilepsy.</description>
</item>
<item>
<title>Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025</title>
<link>https://6ix.com/company/lipocine-inc/news/lipocine-announces-financial-results-second-120000883</link>
<guid isPermaLink="true">https://6ix.com/company/lipocine-inc/news/lipocine-announces-financial-results-second-120000883</guid>
<pubDate>Tue, 05 Aug 2025 12:00:00 GMT</pubDate>
<description>Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced financial results for the second quarter ended June 30, 2025 and provided a corporate update.</description>
</item>
<item>
<title>Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression</title>
<link>https://6ix.com/company/lipocine-inc/news/lipocine-announces-first-patient-dosed-120000394</link>
<guid isPermaLink="true">https://6ix.com/company/lipocine-inc/news/lipocine-announces-first-patient-dosed-120000394</guid>
<pubDate>Thu, 26 Jun 2025 12:00:00 GMT</pubDate>
<description>Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that the first patient has been dosed in its pivotal Phase 3 clinical trial of LPCN 1154 (oral brexanolone), its investigational oral treatment for postpartum depression (PPD).</description>
</item>
<item>
<title>Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025</title>
<link>https://6ix.com/company/lipocine-inc/news/lipocine-host-virtual-r-d-120000354</link>
<guid isPermaLink="true">https://6ix.com/company/lipocine-inc/news/lipocine-host-virtual-r-d-120000354</guid>
<pubDate>Mon, 23 Jun 2025 12:00:00 GMT</pubDate>
<description>Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced that it will host a virtual research and development (R&D) investor event on Wednesday, July 9, 2025 at 11:00 AM ET featuring Kristina M. Deligiannidis, MD (Zucker Hillside Hospital, Northwell Health, New York), who will join company management to discuss the current treatment landscape and unmet needs in postpartum depression</description>
</item>
<item>
<title>Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada</title>
<link>https://6ix.com/company/lipocine-inc/news/lipocine-announces-filing-drug-submission-120000953</link>
<guid isPermaLink="true">https://6ix.com/company/lipocine-inc/news/lipocine-announces-filing-drug-submission-120000953</guid>
<pubDate>Mon, 09 Jun 2025 12:00:00 GMT</pubDate>
<description>Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced that its licensing partner, Verity Pharma, filed a New Drug Submission (NDS) for TLANDO® in Canada. TLANDO is the first and only oral testosterone replacement therapy (TRT) option approved by the US Food and Drug Administration (FDA) that does not require dose titration.</description>
</item>
<item>
<title>Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology</title>
<link>https://6ix.com/company/lipocine-inc/news/lipocines-lpcn-1148-highlighted-june-120000736</link>
<guid isPermaLink="true">https://6ix.com/company/lipocine-inc/news/lipocines-lpcn-1148-highlighted-june-120000736</guid>
<pubDate>Thu, 22 May 2025 12:00:00 GMT</pubDate>
<description>Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that its development candidate LPCN 1148 for men with cirrhosis is featured in the "Hepatology Highlights" section of the June 2025 edition of Hepatology. The article "LPCN 1148: Rebuilding muscle memory in cirrhosis patients" was contributed by Dr. Kevin Harris of the Division of Gastroenterology and Hepatology, Mayo Cl</description>
</item>
<item>
<title>Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase</title>
<link>https://6ix.com/company/lipocine-inc/news/lipocine-present-g-p-annual-120000973</link>
<guid isPermaLink="true">https://6ix.com/company/lipocine-inc/news/lipocine-present-g-p-annual-120000973</guid>
<pubDate>Wed, 14 May 2025 12:00:00 GMT</pubDate>
<description>Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that it will present at A.G.P.'s Annual Healthcare Company Showcase being held virtually on Wednesday, May 21, 2025.</description>
</item>
<item>
<title>Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025</title>
<link>https://6ix.com/company/lipocine-inc/news/lipocine-announces-financial-results-first-120000837</link>
<guid isPermaLink="true">https://6ix.com/company/lipocine-inc/news/lipocine-announces-financial-results-first-120000837</guid>
<pubDate>Thu, 08 May 2025 12:00:00 GMT</pubDate>
<description>Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the first quarter ended March 31, 2025 and provided a corporate update.</description>
</item>
<item>
<title>Lipocine Announces License and Supply Agreement for TLANDO® in Brazil</title>
<link>https://6ix.com/company/lipocine-inc/news/lipocine-announces-license-supply-agreement-120000477</link>
<guid isPermaLink="true">https://6ix.com/company/lipocine-inc/news/lipocine-announces-license-supply-agreement-120000477</guid>
<pubDate>Tue, 06 May 2025 12:00:00 GMT</pubDate>
<description>Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced that it has entered into license and supply agreement with Aché Laboratórios Farmacêuitcos S.A (Aché) granting exclusive rights to market TLANDO® in Brazil.</description>
</item>
</channel>
</rss>